An Israeli company is formulating the first “cannaceutical” aiming to help people with insomnia and other sleep disorders.
The product, called ican.sleep, is a “cannaceutical” (pharmaceutical-grade cannabis product) that is lined up to be launched in the global market following patient trials taking place in Q3 this year.
According to the two companies jointly releasing the product, CannRx and iCAN:Israel-Cannabis, ican.sleep will utilise pharmaceutical-grade delivery systems to provide a stable, controlled dose of cannabis formulation.
It will use a CannRx proprietary technology called CannTrap to capture and stabilise cannabinoids that are “soluble and adequately bioavailable”.
– Read the entire article at AJP News.